Cue Biopharma, Inc.
Cue Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $27.5 million, up 195.7% from fiscal 2024. In the quarter to June 2026, revenue grew 166.7%, EPS fell 793.2% and free cash flow fell 742.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow CUE
Cue Biopharma, Inc. (CUE) P/E ratio
Cue Biopharma, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 29 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MSLE Satellos Bioscience Inc. compare | n/m |
| NKTX Nkarta, Inc. compare | n/m |
| ALXO ALX Oncology Holdings Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| ANTX AN2 Therapeutics, Inc. compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| MOLN Molecular Partners AG Sponsored ADR compare | n/m |
| CUE Cue Biopharma, Inc. | n/m |
| CDXS Codexis, Inc. compare | n/m |
| Biotechnology industry median | 8.4× |
| Healthcare sector median | 22.8× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)